GetTopicDetailResponse(id=324d12821350, topicName=波伏西替尼, introduction=, content=白癜風(fēng) 波伏西替尼, image=null, comments=0, allHits=138, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Mon Jun 30 09:22:27 CST 2025, time=2025-06-30, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=506043, tagList=[TagDto(tagId=506043, tagName=波伏西替尼)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2271399, encodeId=03ac22e139983, content=<a href='/topic/show?id=656be170520' target=_blank style='color:#2F92EE;'>#白癜風(fēng)#</a> <a href='/topic/show?id=324d12821350' target=_blank style='color:#2F92EE;'>#波伏西替尼#</a>, objectTitle=J Am Acad Dermatol：波伏西替尼治療廣泛型白癜風(fēng)的療效與安全性，一項(xiàng)隨機(jī)、雙盲、劑量遞增的2期臨床試驗(yàn), objectType=article, longId=884773, objectId=f944884e73f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250329/1743259000990_8538692.png, objectUrl=/article/show_article.do?id=f944884e73f4, replyNumber=0, likeNumber=32, createdTime=2025-06-30, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f944884e73f4, moduleTitle=J Am Acad Dermatol：波伏西替尼治療廣泛型白癜風(fēng)的療效與安全性，一項(xiàng)隨機(jī)、雙盲、劑量遞增的2期臨床試驗(yàn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f944884e73f4)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-06-30發(fā)表于上海
